By Sheri Kasprzak
New York, Nov. 21 - EpiCept Corp. said it has concluded a $2 million private placement of senior convertible notes due Oct. 30, 2006.
The 8% notes were purchased by TVM Techno Venture Management, Private Equity Direct Finance, Merlin General Partners II Ltd., NIBC Principal Instruments IV BV, Claus Dieckell and Freidrich Dieckell.
The notes are convertible into common shares $0.71 each and may be prepaid at any time without penalty.
Proceeds will be used for working capital.
Based in Englewood Cliffs, N.J., EpiCept is a biopharmaceutical company focused on topical treatments for pain.
| Issuer: | EpiCept Corp.
|
| Issue: | Senior convertible notes
|
| Amount: | $2 million
|
| Maturity: | Oct. 30, 2006
|
| Coupon: | 8%
|
| Price: | Par
|
| Yield: | 8%
|
| Conversion price: | $0.71
|
| Warrants: | No
|
| Investors: | TVM Techno Venture Management, Private Equity Direct Finance, Merlin General Partners II Ltd., NIBC Principal Instruments IV BV, Claus Dieckell and Freidrich Dieckell
|
| Settlement date: | Nov. 17
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
